Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 27, 2024
Daily News
February 27, 2024
- Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
- NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
February 27, 2024
- JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
- Show Change in Development Trends before Seeking 2026 Reform: MHLW to Pharma
February 27, 2024
- Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…